Federal Register Notice: FDA is establishing a docket to receive suggestions, recommendations, and comments from interested parties on best practices for communication between FDA and investigational new drug application (IND) sponsors during drug development. These comments will help FDA identify and ultimately establish best practices to be included in a draft guidance for industry and review staff. Comments should be submitted by 12/29. To view this notice, click here.